Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Hui Wen Chan; Yi Hsuan Lo; Deng Yuan Chang; Jia Je Li; Wen Yi Chang; Chih Hao Chen; Chih Hsien Chang; Chuan Lin Chen; Hsin Ell Wang; Ren Shyan Liu; Chun Yi Wu

doi:10.3390/gels8030180

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Hui Wen Chan, Yi Hsuan Lo, Deng Yuan Chang, Jia Je Li, Wen Yi Chang, Chih Hao Chen, Chih Hsien Chang, Chuan Lin Chen, Hsin Ell Wang, Ren Shyan Liu, Chun Yi Wu^*

^*Corresponding author for this work

Department of Biomedical Imaging and Radiological Sciences

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (¹¹¹In/¹⁷⁷Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of¹¹¹In/¹⁷⁷Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the¹¹¹In/¹⁷⁷Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of¹⁷⁷Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of¹⁷⁷Lu-DTPA-CMS in the treatment of N1-S1 hepatoma.¹¹¹In/¹⁷⁷Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.

Original language	English
Article number	180
Journal	Gels
Volume	8
Issue number	3
DOIs	https://doi.org/10.3390/gels8030180
State	Published - Mar 2022

Keywords

hepatocellular carcinoma (HCC)
radiolabeled chitosan microspheres (In/Lu-DTPA-CMS)
theranostics
transarterial radioembolization (TARE)

Access to Document

10.3390/gels8030180

Cite this

@article{283a3b3be1bf4fd9bf76045aece9b7c5,

title = "Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma",

abstract = "Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (111In/177Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of111In/177Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the111In/177Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of177Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of177Lu-DTPA-CMS in the treatment of N1-S1 hepatoma.111In/177Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.",

keywords = "hepatocellular carcinoma (HCC), radiolabeled chitosan microspheres (In/Lu-DTPA-CMS), theranostics, transarterial radioembolization (TARE)",

author = "Chan, {Hui Wen} and Lo, {Yi Hsuan} and Chang, {Deng Yuan} and Li, {Jia Je} and Chang, {Wen Yi} and Chen, {Chih Hao} and Chang, {Chih Hsien} and Chen, {Chuan Lin} and Wang, {Hsin Ell} and Liu, {Ren Shyan} and Wu, {Chun Yi}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

doi = "10.3390/gels8030180",

language = "English",

volume = "8",

journal = "Gels",

issn = "2310-2861",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

AU - Chan, Hui Wen

AU - Lo, Yi Hsuan

AU - Chang, Deng Yuan

AU - Li, Jia Je

AU - Chang, Wen Yi

AU - Chen, Chih Hao

AU - Chang, Chih Hsien

AU - Chen, Chuan Lin

AU - Wang, Hsin Ell

AU - Liu, Ren Shyan

AU - Wu, Chun Yi

PY - 2022/3

Y1 - 2022/3

N2 - Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (111In/177Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of111In/177Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the111In/177Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of177Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of177Lu-DTPA-CMS in the treatment of N1-S1 hepatoma.111In/177Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.

AB - Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (111In/177Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of111In/177Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the111In/177Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of177Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of177Lu-DTPA-CMS in the treatment of N1-S1 hepatoma.111In/177Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.

KW - hepatocellular carcinoma (HCC)

KW - radiolabeled chitosan microspheres (In/Lu-DTPA-CMS)

KW - theranostics

KW - transarterial radioembolization (TARE)

UR - http://www.scopus.com/inward/record.url?scp=85127025286&partnerID=8YFLogxK

U2 - 10.3390/gels8030180

DO - 10.3390/gels8030180

M3 - Article

AN - SCOPUS:85127025286

SN - 2310-2861

VL - 8

JO - Gels

JF - Gels

IS - 3

M1 - 180

ER -

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this